Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Tablets: SOP for API Retention Time Validation for Tablets – V 2.0

Posted on By

Tablets: SOP for API Retention Time Validation for Tablets – V 2.0

Standard Operating Procedure for API Retention Time Validation for Tablets

Department Quality Control
SOP No. SOP/TAB/115/2025
Supersedes SOP/TAB/115/2022
Page No. Page 1 of 7
Issue Date 01/03/2026
Effective Date 06/03/2026
Review Date 01/03/2027

1. Purpose

To define the procedure for validating the retention time of the active pharmaceutical ingredient (API) in tablet formulations using High-Performance Liquid Chromatography (HPLC), ensuring consistency and accuracy in API identification and quantification.

2. Scope

This SOP applies to the validation of retention times for the API in tablet formulations using HPLC. The method ensures that the retention time of the API is consistent with established specifications and provides reliable data for quality control and regulatory compliance.

3. Responsibilities

  • Quality Control (QC): Responsible for performing retention time validation and ensuring that the results comply with specifications.
  • Quality Assurance (QA): Ensures that the retention time validation is performed according to the SOP and reviews the results for compliance with regulatory standards.
  • Laboratory Personnel: Responsible for preparing samples, operating the HPLC system, and recording results accurately.

4. Accountability

The QC Manager is accountable for ensuring the accurate performance of retention time validation. The QA Manager is responsible for

reviewing and approving the results to ensure consistency and reliability in API testing.

See also  Tablets: SOP for Investigating Tablet Coating Defects - V 2.0

5. Procedure

5.1 Sample Preparation

  1. Weigh an appropriate amount of tablet sample (usually 10 tablets) to obtain a representative quantity for testing.
  2. Crush the tablets to a fine powder using a mortar and pestle or mechanical grinder to ensure uniformity.
  3. Dissolve the powder in an appropriate solvent (e.g., methanol or acetonitrile) based on the solubility of the API, and filter the solution using a 0.45 µm filter.
  4. If necessary, dilute the solution to bring the concentration within the optimal range for HPLC analysis.

5.2 HPLC System Setup

  1. Ensure that the HPLC system is properly calibrated and the appropriate column is installed for API separation.
  2. Set up the mobile phase, flow rate, and other conditions (e.g., temperature, detection wavelength) based on the method validation specifications.
  3. Prime the system to ensure consistent flow and eliminate air bubbles in the pump or lines.

5.3 Retention Time Validation

  1. Inject a known standard of the API into the HPLC system to establish a baseline retention time under the selected conditions.
  2. Inject the prepared tablet sample and record the retention time for the API peak in the chromatogram.
  3. Compare the retention time of the tablet sample with that of the standard. The retention time should match within an acceptable range (typically ±5% of the standard’s retention time).
  4. Perform the test in triplicate to ensure reproducibility of the results.
See also  Tablets: SOP for Ensuring Batch Code Legibility on Packaging - V 2.0

5.4 Data Analysis and Calculation

  1. Calculate the average retention time for the API from the triplicate injections.
  2. Ensure that the average retention time falls within the specified range of the standard’s retention time. Any significant deviations must be investigated.
  3. Document all observations and results, including chromatograms, retention time data, and any deviations from the expected results.

5.5 Acceptance Criteria

  1. The retention time of the API should be consistent with the standard within the allowable limits (±5%).
  2. If the retention time falls outside the acceptable range, initiate an investigation to identify potential issues, such as incorrect mobile phase composition, column problems, or sample contamination.
  3. Corrective actions should be taken as necessary, and re-testing should be performed once the issue is resolved.

5.6 Documentation and Record-Keeping

  1. Record all validation results, including chromatograms, retention time calculations, and observations in the batch record (Annexure-2).
  2. Ensure that all records are signed, dated, and stored according to the company’s record retention policy for future audits and inspections.
  3. Maintain raw data, including instrument logs, standard preparation details, and deviation reports, for regulatory compliance and future reference.

5.7 Post-Test Actions

  1. Clean the HPLC system and associated equipment to remove any residual sample and prevent cross-contamination between tests.
  2. Dispose of used samples, solvents, and reagents according to the company’s waste disposal procedures.
  3. Ensure that the HPLC system is calibrated and maintained according to the manufacturer’s guidelines and company SOPs.
See also  Tablets: SOP for Leak Testing of Blister Packs - V 2.0

6. Abbreviations

  • SOP: Standard Operating Procedure
  • GMP: Good Manufacturing Practice
  • QC: Quality Control
  • QA: Quality Assurance
  • API: Active Pharmaceutical Ingredient
  • HPLC: High-Performance Liquid Chromatography

7. Documents

  1. Batch Record (Annexure-2)
  2. Deviation Report (Annexure-1)

8. References

  • USP <621> – Chromatography
  • 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals (US FDA)
  • European Pharmacopoeia (EP) – Specifications for Chromatography and Method Validation

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Deviation Report

Deviation Date Batch Number Deviation Description Corrective Action Responsible Person
15/12/2025 Batch 001 Retention time variation beyond acceptable limit Re-calibrated HPLC system and re-tested Jane Smith

Annexure-2: Batch Record

Batch Number Sample Weight (g) API Retention Time (min) Result
Batch 001 100 g 8.5 min Pass

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial Version New SOP Creation QA Head
01/02/2025 2.0 Updated retention time limits Improved precision and accuracy QA Head
Tablet Manufacturing V2.0 Tags:GMP tablet manufacturing SOP, SOP for tablet production, SOP for tablet quality control, SOP tablet inspection process, SOP tablet packing and sealing, Tablet batch record review, Tablet blending SOP, Tablet cleaning and maintenance, Tablet coating procedure, Tablet compression SOP, Tablet disintegration test procedure, Tablet dissolution procedure, Tablet formulation SOP, Tablet friability testing SOP, Tablet labeling and packaging SOP, Tablet manufacturing equipment SOP, Tablet manufacturing SOP, Tablet manufacturing SOPs, Tablet packaging SOP, Tablet production procedure, Tablet quality assurance SOP, Tablet quality control SOP, Tablet sampling and in-process testing SOP, Tablet stability testing SOP, Tablet storage and handling procedure, Tablet uniformity testing procedure, Tablet weight variation SOP

Post navigation

Previous Post: Capsule: SOP for Handling Controlled Substances in Dispensing – V 2.0
Next Post: Job Safety Analysis for Fluid Bed Processor

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version